Update on the role of antipsychotics in the treatment of Tourette syndrome

Neuropsychiatric Disease and Treatment

Volumn 8, Issue , 2012, Pages 95-104

  Huys, Daniel ^a   Hardenacke, Katja ^a   Poppe, Pia ^a   Bartsch, Christina ^a   Baskin, Burak ^a   Kuhn, Jens ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Antipsychotics; Neuroleptics; Tourette; Tourette syndrome

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLONIDINE; CLOZAPINE; DOPAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; PLACEBO; PROPRANOLOL; QUETIAPINE; RISPERIDONE; SULPIRIDE; TETRABENAZINE; TIAPRIDE; ZIPRASIDONE;

AGRANULOCYTOSIS; AMENORRHEA; BASAL GANGLION; BRAIN DYSFUNCTION; DEPRESSION; DOPAMINERGIC SYSTEM; DROWSINESS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; GALACTORRHEA; GILLES DE LA TOURETTE SYNDROME; HEART ARRHYTHMIA; HUMAN; HYPERPROLACTINEMIA; INCREASED APPETITE; INSOMNIA; MEDLINE; MOTOR DYSFUNCTION; MYOCLONUS SEIZURE; NAUSEA; NEUROLEPTIC MALIGNANT SYNDROME; PARKINSONISM; PATHOPHYSIOLOGY; PSYCHOSOCIAL DISORDER; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; RESTLESSNESS; REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; STUTTERING; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TIC; TREMOR; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN;

EID: 84930480116     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S12990     Document Type: Review

References (131)

1. Mink JW. Neurobiology of basal ganglia and Tourette syndrome: basal ganglia circuits and thalamocortical outputs. Adv Neurol. 2006; 99:89-98.
2. Jankovic J. Differential diagnosis and etiology of tics. Adv Neurol. 2001;85:15-29.
3. Wong DF, Brasić JR, Singer HS, et al. Mechanisms of dopaminergic and serotengeric neurotransmission in Tourette syndrome: clues from an in vivo neurochemistry study with PET. Neuropsychopharmacology. 2008:33(6):1239-1251.
4. Wong DF, Singer HS, Brandt J, et al. D2-like dopamine receptor density in Tourette syndrome measured by PET. J Nucl Med. 1997: 38(8):1243-1247.
5. Yoon DY, Gause CD, Leckman JF, Singer HS. Frontal dopaminergic abnormality in Tourette syndrome: a postmortem analysis. J Neurol Sci. 2007:255(1-2):50-56.
6. Yeh CB, Lee CH, Chou YH, Chang CJ, Ma KH, Huang WS. Evaluating dopamine transporter activity with 99 mTc-TRODAT-1 SPECT in drugnaive Tourette's adults. Nucl Med Commun. 2006;27(10):779-784.
7. Yeh CB, Lee CS, Ma KH, Lee MS, Chang CJ, Huang WS. Phasic dysfunction of dopamine transmission in Tourette's syndrome evaluated with (99 m)Tc TRODAT-1 imaging. Psychiatry Res. 2007; 156(1):75-82.
8. Gilbert D. Treatment of children and adolescents with tics and Tourette syndrome. J Child Neurol. 2006;21(8):690-700.
9. Roessner V, Plessen KJ, Rothenberger A, et al. European clinical guidelines for Tourette syndrome and other tic disorders. Part II: pharmacological treatment. Eur Child Adolesc Psychiatry. 2011;20(4): 173-196.
10. Scahill L, Erenberg G, Berlin CM Jr, et al. Contemporary assessment and pharmacotherapy of Tourette syndrome. Neuro Rx. 2006;3(2): 192-206.
11. Singer HS. Treatment of tics and tourette syndrome. Curr Treat Options Neurol. 2010;12(6):539-561.
12. Azrin NH, Nunn RG. Habit reversal: a method of eliminating nervous habits and tics. Behav Res Ther. 1973;11(4):619-628.
13. Kuhn J, Gründler TO, Lenartz D, Sturm V, Klosterkötter J, Huff W. Deep brain stimulation for psychiatric disorders. Dtsch Arztebl Int. 2010;107(7):105-113.
14. Rickards H, Hartley N, Robertson MM. Seignot's paper on the treatment of Tourette's syndrome with haloperidol. Hist Psychiatry. 1997; 8(31 Pt 3):433-436.
15. Parraga HC, Harris KM, Parraga KL, Balen GM, Cruz C. An overview of the treatment of Tourette's disorder and tics. J Child Adolesc Psychopharmacol. 2010;20(4):249-262.
16. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 1989;46(8):722-730.
17. Shapiro AK, Shapiro ES, Young JG, Feinberg TE. Gilles de la Tourette Syndrome. 2nd ed. New York: Raven Press; 1988.
18. Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatry. 1978;135(5):585-587.
19. Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry. 1997;154(8):1057-1062.
20. Sandor P, Musisi S, Moldofsky H, Lang A. Tourette syndrome: a follow-up study. J Clin Psychopharmacol. 1990;10(3):197-199.
21. Borison RL, Ang L, Hamilton WJ, Diamond BI, Davis JM. Treatment approaches in Gilles de la Tourette syndrome. Brain Res Bull. 1983; 11(2):205-208.
22. Eddy CM, Rickards HE, Cavanna AE. Treatment strategies for tics in Tourette syndrome. Ther Adv Neurol Disord. 2011;4(1):25-45.
23. Gulisano M, Cali PV, Cavanna AE, Eddy C, Rickards H, Rizzo R. Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome. Neurol Sci. 2011;32(6):1213-1217.
24. Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev. 2009;(2):CD006996.
25. Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallelgroup study. J Clin Psychiatry. 2001;62(1):50-56.
26. Gilbert DL, Batterson JR, Sethuraman G, Sallee FR. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004;43(2):206-214.
27. Silay YS, Vuong KD, Jankovic J. The efficacy and safety of fluphenazine in patients with Tourette syndrome. Neurology. 2004;62(Suppl 5): A506.
28. Jankovic J, Jimenez-Shahed J, Brown LW. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2009;81(1):70-73.
29. Borison RL, Ang L, Chang S, Dysken M, Comaty JE, Davis JM. New pharmacological approaches in the treatment of Tourette syndrome. Adv Neurol. 1982;35:377-382.
30. Goetz CG, Tanner CM, Klawans HL. Fluphenazine and multifocal tic disorders. Arch Neurol. 1984;41(3):271-272.
31. Singer HS, Gammon K, Quaskey S. Haloperidol, fluphenazine and clonidine in Tourette syndrome: controversies in treatment. Pediatr Neurosci. 1985-1986;(2)12:71-74.
32. Müller-Vahl KR. The benzamides tiapride, sulpiride, and amisulpride in treatment of Tourette's syndrome. Nervenarzt. 2007;78(3):264-271.
33. Dose M, Lange HW. The benzamine tiapride: treatment of extrapyramidal motor and other clinical syndromes. Pharmacopsychiatry. 2000; 33(1):19-27.
34. Meisel A, Winter C, Zschenderlein R, Arnold G. Tourette syndrome: efficient treatment with ziprasidone and normalization of body weight in a patient with excessive weight gain under tiapride. Mov Disord. 2004;19(8):991-992.
35. Scatton B, Cohen C, Perrault G, et al. The preclinical pharmacologic profile of tiapride. Eur Psychiatry. 2001;16 Suppl 1:29s-34s.
36. Bock N, Moll GH, Wicker M, et al. Early administration of tiapride to young rats without long-lasting changes in the development of the dopaminergic system. Pharmacopsychiatry. 2004;37(4):163-167.
37. Drtilkova I. Clonazepam, clonidine and tiapride in children with tic disorder. Homeostasis. 1996;37(5):216.
38. Klepel H, Gebelt H, Koch RD, Tzenow H. Treatment of extrapyramidal hyperkineses in childhood with tiapride. Psychiatr Neurol Med Psychol (Leipz). 1988;40(9):516-522.
39. Lipcsey A. Gilles de la Tourette's disease. Sem Hop. 1983;59(10): 695-696.
40. Eggers C, Rothenberger A, Berghaus U. Clinical and neurobiological findings in children suffering from tic disease following treatment with tiapride. Eur Arch Psychiatry Neurol Sci. 1988;237(4):223-229.
41. Pani L, Gessa GL. The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia. Mol Psychiatry. 2002;7(3):247-253.
42. Yvonneau M, Bezard P. Apropos of a case of Gilles de la Tourette's disease blocked by sulpiride. Psycho-biological study. Encephale. 1970; 59(5):439-459.
43. Ruther E, Degner D, Munzel U. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial. Pharmacopsychiatry. 1999;32(4):127-135.
44. Robertson MM, Schneider V, Lees AJ. Management of Gilles de la Tourette syndrome using sulpiride. Clin Neuropsychopharmacol. 1990;13(3):229-235.
45. Huang TL, Lu CY. Correlations between weight changes and lipid profile changes in schizophrenic patients after antipsychotics therapy. Chang Gung Med J. 2007;30(1):26-32.
46. Wetterling T, Mussigbrodt HE. Weight gain: side effect of atypical neuroleptics? J Clin Psychopharmacol. 1999;19(4):316-321.
47. Ho CS, Chen HJ, Chiu NC, Shen EY, Lue HC. Short-term sulpiride treatment of children and adolescents with Tourette syndrome or chronic tic disorder. J Formos Med Assoc. 2009;108(10): 788-793.
48. George MS, Trimble MR, Robertson MM. Fluvoxamine and sulpiride in comorbid obsessive-compulsive disorder and Gilles-De-La-Tourette syndrome. Hum Psychopharmacol Clin Exp. 1993;8:327-334.
49. Trillet M, Moreau T, Dalery J, de Villard R, Aimard G. Treatment of Gilles de la Tourette's disease with amisulpride. Presse Med. 1990; 19(4):175.
50. Fountoulakis KN, Iacovides A, St Kaprinis G. Successful treatment of Tourette's disorder with amisulpride. Ann Pharmacother. 2004; 38(5):901.
51. Kozian R, Friedrich M. Gilles-de-la-Tourette Syndrome as a Tardive Dyskinesia. Psychiatr Prax. 2007;34(5):253-254.
52. Crilly J. The history of clozapine and its emergence in the US market: a review and analysis. Hist Psychiatry. 2007;18(1):39-60.
53. Jaffe E, Tremeau F, Sharif Z, Reider R. Clozapine in tardive Tourette syndrome. Biol Psychiatry. 1995;38(3):196-197.
54. Kalian M, Lerner V, Goldman M. Atypical variants of tardive dyskinesia, treated by a combination of clozapine with propanolol and clozapine with tetrabenazine. J Nerv Ment Dis. 1993;181(10):649-651.
55. Caine ED, Polinsky RJ, Kartzinel R, Ebert MH. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry. 1979;136(3):317-320.
56. Begum M. Clozapine-induced stuttering, facial tics and myoclonic seizures: a case report. Aust N Z J Psychiatry. 2005;39(3):202.
57. Bastiampillai T, Dhillon R, Mohindra R. Exacerbation of tics secondary to clozapine therapy. Aust N Z J Psychiatry. 2008;42(12):1068-1070.
58. Kim BN, Lee CB, Hwang JW, Shin MS, Cho SC. Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea. J Child Adolesc Psychopharmacol. 2005;15(2):318-324.
59. van der Linden C, Bruggeman R, van Woerkom TC. Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dosetitration study with risperidone. Mov Disord. 1994;9(6):687-688.
60. Diantoniis MR, Henry KM, Partridge PA, Soucar E. Tics and risperidone. J Am Acad Child Adolesc Psychiatry. 1996;35(7):839-840.
61. Stamenkovic M, Aschauer H, Kasper S. Risperidone for Tourette's syndrome. Lancet. 1994;344(8936):1577-1578.
62. Zhao H, Zhu Y. Risperidone in the treatment of Tourette syndrome. Ment Health J. 2003;17:30.
63. Scahill L, Leckman JF, Schultz RT, Katsovich L, Peterson BS. A placebo-controlled trial of risperidone in Tourette syndrome. Neurology. 2003;60(7):1130-1135.
64. Dion Y, Annable L, Sandor P, Chouinard G. Risperidone in the treatment of tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol. 2002;22(1):31-39.
65. Lim LK, Shin SY. Risperidone versus Haloperidol in the treatment of children with Tourette's Syndrome and chronic motor or vocal tic disorder in Korea. Eur Neuropsychopharacol. 2006;16:5527.
66. Gaffney GR, Perry PJ, Lund BC, Bever-Stille KA, Arndt S, Kuperman S. Risperidone versus clonidine in the treatment of children and adolescents with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry. 2002;41(3):330-336.
67. Bruun RD, Budman CL. Risperidone as a treatment for Tourette's syndrome. J Clin Psychiatry. 1996;57(1):29-31.
68. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry. 1995;34(9):1147-1152.
69. Shulman LM, Singer C, Weiner WJ. Risperidone in Gilles de la Tourette syndrome. Neurology. 1995;45(7):1419.
70. Robertson MM, Scull DA, Eapen V, Trimble MR. Risperidone in the treatment of Tourette syndrome: a retrospective case note study. Psychopharmacol. 1996;10(4):317-320.
71. Chappell PB, Leckman JF, Riddle MA. The pharmacological treatment of tic disorders. Child Adolesc Psychiatric Clin North Am. 1995;4: 197-216.
72. Giakas WJ. Risperidone treatment for a Tourette's disorder patient with comorbid obsessive-compulsive disorder. Am J Psychiatry. 1995; 152(7):1097-1098.
73. Sandor P, Stephens RJ. Risperidone treatment of aggressive behavior in children with Tourette syndrome. J Clin Psychopharmacol. 2000; 20(6):710-712.
74. Pappadopulos E, Woolston S, Chait A, Perkins M, Connor DF, Jensen PS. Pharmacotherapy of aggression in children and adolescents: efficacy and effect size. J Can Acad Child Adolesc Psychiatry. 2006; 15(1): 27-39.
75. Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette's syndrome-a pilot study. J Child Adolescent Psychopharmacol. 2004;14(2):255-266.
76. Budman CL, Gayer A, Lesser M, Shi Q, Bruun RD. An open-label study of the treatment efficacy of olanzapine for Tourette's disorder. J Clin Psychiatry. 2001;62(4):290-294.
77. McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol. 2008;18(5):501-508.
78. http://www.lilly.com. Zyprexa product label. Available from: http:// pi.lilly.com/us/zyprexa-pi.pdf. Accessed September 28, 2011.
79. Ji WD, Li Y, Li N, Guo BY. Olanzapine for treatment of Tourette syndrome: a double-blind randomized controlled trial. Chinese J Clin Rehab. 2005;9:66-68.
80. Onofrj M, Paci C, D'Andreamatteo G, Toma L. Olanzapine in severe Gilles de la Tourette syndrome: a 52-week double-blind cross-over study vs low-dose pimozide. J Neurol. 2000;247(6):443-446.
81. Bengi Semerci Z. Olanzapine in Tourette's disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(2):140.
82. Bhadrinath BR. Olanzapine in Tourette syndrome. Br J Psychiatry. 1998;172:366.
83. Karam-Hage M, Ghaziuddin N. Olanzapine in Tourette's disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(2):139.
84. Lucas Taracena MT, Montanes Rada F. Olanzapine in Tourette's syndrome: a report of three cases. Actas Esp Psiquiatr. 2002;30(2): 129-132.
85. Krishnamoorthy J, King BH. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol. 1998;8(2):107-113.
86. Stamenkovic M, Schindler SD, Aschauer HN, et al. Effective openlabel treatment of tourette's disorder with olanzapine. Int Clin Psychopharmacol. 2000;15(1):23-28.
87. Parraga HC, Parraga MI, Woodward RL, Fenning PA. Quetiapine treatment of children with Tourette's syndrome: report of two cases. J Child Adolesc Psychopharmacol. 2001;11(2):187-191.
88. Mukaddes NM, Abali O. Quetiapine treatment of children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2003;13(3):295-299.
89. Copur M, Arpaci B, Demir T, Narin H. Clinical effectiveness of quetiapine in children and adolescents with Tourette's syndrome: a retrospective case-note survey. Clin Drug Investig. 2007;27(2): 123-130.
90. Keck PE Jr, McElroy SL, Arnold LM. Ziprasidone: a new atypical antipsychotic. Expert Opin Pharmacother. 2001;2(6): 1033-1042.
91. Sallee FR, Kurlan R, Goetz CG, et al. Ziprasidone treatment of children and adolescents with Tourette's syndrome: a pilot study. J Am Acad Child Adolesc Psychiatry. 2000;39(3):292-299.
92. Stahl SM, Shayegan DK. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry. 2003;64 Suppl 19:6-12.
93. Sallee FR, Miceli JJ, Tensfeldt T, Robarge L, Wilner K, Patel NC. Single-dose pharmacokinetics and safety of ziprasidone in children and adolescents. J Am Acad Child Adolesc Psychiatry. 45(6):720-728.
94. Willmund G, Lee AH, Wertenauer F, et al. Vocal tics associated with ziprasidone. J Clin Psychopharmacol. 2009;29(6):611-612.
95. Budman C, Coffey BJ, Shechter R, et al. Aripiprazole in children and adolescents with Tourette disorder with and without explosive outbursts. J Child Adolesc Psychopharmacol. 2008;18(5):509-515.
96. Wood M, Reavill C. Aripiprazole acts as a selective dopamine D2 receptor partial agonist. Expert Opin Investig Drugs. 2007;16(6): 771-775.
97. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002;441(3):137-140.
98. Ben Djebara M, Worbe Y, Schopbach M, Hartmann A. Aripiprazole: a treatment for severe coprolalia in "refractrory" Gilles de la Tourette syndrome. Mov Disord. 2008;15;23(3):438-440.
99. Bubl E, Perlov E, Tebartz Van Elst L. Aripiprazole in patients with Tourette syndrome. World J Biol Psychiatry. 2006;7(2):123-125.
100. Constant EL, Borras L, Seghers A. Aripiprazole is effective in the treatment of Tourette's disorder. Int J Neuropsychopharmacol. 2006; 9(6):773-774.
101. Cui YH, Zheng Y, Yang YP, Liu J, Li J. Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: a pilot study in China. J Child Adolesc Psychopharmacol. 2010;20(4): 291-298.
102. Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol. 2006;21(7):447-453.
103. Dehning S, Riedel M, Muller N. Aripiprazole in a patient vulnerable to adverse reactions. Am J Psychiatry. 2005;162(3):625.
104. Duane DD. Aripiprazole in childhood and adolescence for Tourette syndrome. J Child Neurol. 2006;21(4):358.
105. Fountoulakis KN, Siamouli M, Kantartzis S, Panagiotidis P, Iacovides A, Kaprinis GS. Acute dystonia with low-dosage aripiprazole in Tourette's disorder. Ann Pharmacother. 2006;40(4): 775-777.
106. Hood KK, Lourival BN, Beasley PJ, Lobis R, Pravdova, I. Case study: severe self-injurious behavior in comorbid Tourette's disorder and OCD. J Am Acad Child Adolesc Psychiatry. 2004;43(10): 1296-1303.
107. Hounie A, De Mathis A, Sampaio AS, Mercadante MT. Aripiprazole and Tourette syndrome. Rev Bras Psiquiatr. 2004;26(3):213.
108. Ikenouchi-Sugita A, Yoshimura R, Hayashi K, et al. A case of lateonset Tourette's disorder successfully treated with aripiprazole: view from blood levels of catecholamine metabolites and brainderived neurotrophic factor (BDNF). World J Biol Psychiatry. 2009; 10(4 Pt 3):977-980.
109. Kastrup A, Schlotter W, Plewnia C, Bartels M. Treatment of tics in tourette syndrome with aripiprazole. J Clin Psychopharmacol. 2005; 25(1):94-96.
110. Kawohl W, Schneider F, Vernaleken I, Neuner I. Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients. World J Biol Psychiatry. 2009;10(4 Pt 3):827-831.
111. Kawohl W, Schneider F, Vernaleken I, Neuner I. Chronic motor tic disorder and aripiprazole. J Neuropsychiatry Clin Neurosci. 2009; 21(2):224.
112. Lyon GJ, Samar S, Jummani R, et al. Aripiprazole in children and adolescents with Tourette's disorder: an open-label safety and tolerability study. J Child Adolesc Psychopharmacol. 2009;19(6): 623-633.
113. Miranda CM, Castiglioni TC. Aripiprazole for the treatment of Tourette syndrome. Experience in 10 patients. Rev Med Chil. 2007; 135(6):773-776.
114. Murphy TK, Bengtson MA, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol. 2005;8(3):489-490.
115. Murphy TK, Mutch PJ, Reid JM, et al. Open label aripiprazole in the treatment of youth with tic disorders. J Child Adolesc Psychopharmacol. 2009;19(4):441-447.
116. Padala PR, Qadri SF, Madaan V. Aripiprazole for the treatment of Tourette's disorder. Prim Care Companion J Clin Psychiatry. 2005; 7(6):296-299.
117. Seo WS, Sung HM, Sea HS, Bai DS. Aripiprazole treatment of children and adolescents with Tourette disorder or chronic tic disorder. J Child Adolesc Psychopharmacol. 2008;18(2):197-205.
118. Winter C, Heinz A, Kupsch A, Strohle A. Aripiprazole in a case presenting with tourette syndrome and obsessive-compulsive disorder. J Clin Psychopharm. 2008;28(4):452-454.
119. Yoo HK, Choi SH, Park S, Wang HR, Hong JP, Kim CY. An openlabel study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry. 2007;68(7): 1088-1093.
120. Yoo HK, Kim JY, Kim CY. A pilot study of aripiprazole in children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol. 2006;16(4):505-506.
121. Pae CU. A review of the safety and tolerability of aripiprazole. Expert Opin Drug Saf. 2009;8(3):373-386.
122. Müller-Vahl KR, Rothenberger A, Roessner V, Poewe W, Vingerhoets F, Münchau A. Guidelines for diagnosis and treatment: Tic disorders. In: Diener HC, Putzki N, editors. Guidelines for Diagnosis and Therapy in Neurology. Stuttgart, Thieme; 2008:125-129. German.
123. Rothenberger A, Banaschewski T, Roessner V. Tic disorders. German Society for Child and Adolescent Psychiatry PuP, editor. Guidelines for Diagnosis and Treatment of Mental Disorders in Infancy, Childhood and Adolescence. Köln, Deutscher Ärzteverlag; 2007:319-325. German.
124. http://www.dgn.org. Guidelines of the German Society for Neurology: Available from: http://www.dgn.org/images/stories/dgn/leitlinien/ LL2008/ll08kap_012.pdf. Accessed August 12, 2011. German.
125. Shahid M, Walker GB, Zorn SH, Wong EH. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol. 2009;23(1):65-73.
126. Pompili M, Venturini P, Innamorati M, et al. The role of asenapine in the treatment of manic or mixed states associated with bipolar I disorder. Neuropsychiatr Dis Treat. 2011;7:259-265.
127. Azorin JM, Kaladjian A, Fakra E, Adida M. Sertindole for the treatment of schizophrenia. Expert Opin Pharmacother. 2010;11(18): 3053-3064.
128. Fountoulakis KN, Samara M, Siapera M, Iacovides A. Tardive Tourettelike syndrome: a systematic review. Int Clin Psychopharmacol. 2011; 26(5):237-242.
129. Jankovic J, Kurlan R. Tourette syndrome: evolving concepts. Mov Disord. 2011;26(6):1149-1156.
130. Scahill L, Chappell PB, Kim YS, et al. A placebo controlled study of guanfacine in the treatment of children with tic disorders and attention deficit hyperactivity disorder. Am J Psychiatry. 2001;158(7): 1067-1074.
131. Cummings DD, Singer HS, Krieger M, et al. Neuropsychiatric effects of guanfacine in children with mild tourette syndrome: a pilot study. Clin Neuropharmacol. 2002;25(6):325-332.